



PTO/SB/08B (07-05)
Approved for use through 07/31/2006 OMB 0651-0051
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/551,874
Filing Date	September 30, 2005
First Named Inventor	RUSSWURM
Art Unit	
Examiner Name	
Attorney Docket Number	9740-1

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/STK/		Database NETAFFX; 15 March 2006 http://www.aaffymetrix.com/analysis/netaffx/probematch/probe_match.affx?netaffx=netaffx4_annot	
		Ray et al. "Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future", 2000, Medical and Biotechnical Applications of PNA, 14:1041-1060	
		Jansen et al. "Antisense therapy for cancer - the time of truth", 2002, The Lancet Oncology, 3:672-683	
		Galdersi et al. "Antisense Oligonucleotides as Therapeutic Agents", 1999, Journal of Cellular Physiology, 181:251-257	
		Riesewijk et al. "Gene expression profiling of human endometrial receptivity on days LH+2 versus LH+7 by microarray technology", 2003, 9(5):253-264	
		Liu et al. "Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray", 2004, 114(4):783-790	
		Tsukahara et al. "Gene Expression in Human Neutrophils During Activation and Priming by Bacterial Lipopolysaccharide", 2003, Journal of Cellular Biochemistry, 89:848-861	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/09/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.